ERR2598071
fetal · fetal
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- fetal
- cancer_type_detailed
- —
- subtype
- fetal
- cancer_type
- fetal
- subtype
- fetal
- sex
- fetal
- race
- fetal
- fetal_age_forebrain
- 11
- umap1_2d
- -4.177114163
- umap2_2d
- 1.586646924
- umap1_3d
- -2.275416931
- umap2_3d
- 2.309120423
- umap3_3d
- -2.396202267
- dataset
- fetal
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.550
- E2F_TARGETS+0.520
- G2M_CHECKPOINT+0.500
- WNT_BETA_CATENIN_SIGNALING+0.430
- DNA_REPAIR+0.420
- MYC_TARGETS_V1+0.410
- NOTCH_SIGNALING+0.310
- CHOLESTEROL_HOMEOSTASIS+0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.300
- MITOTIC_SPINDLE+0.270
Top 10 suppressed
- PROTEIN_SECRETION-0.380
- ALLOGRAFT_REJECTION-0.310
- INTERFERON_GAMMA_RESPONSE-0.300
- IL6_JAK_STAT3_SIGNALING-0.280
- INFLAMMATORY_RESPONSE-0.260
- INTERFERON_ALPHA_RESPONSE-0.230
- ANDROGEN_RESPONSE-0.180
- TNFA_SIGNALING_VIA_NFKB-0.130
- KRAS_SIGNALING_UP-0.110
- PI3K_AKT_MTOR_SIGNALING-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2598072 | fetal | fetal | 0.892 |
| 2 | TCGA-85-A4CN-01A-11R-A24H-07 | — | cohortSQ2 | 0.852 |
| 3 | MDT-AP-0347 | Med | Medulloblastoma | 0.843 |
| 4 | TCGA-85-6798-01A-11R-1949-07 | — | cohortSQ2 | 0.830 |
| 5 | ERR2598207 | fetal | fetal | 0.823 |
| 6 | ERR2598252 | fetal | fetal | 0.816 |
| 7 | SRR12475126 | — | — | 0.813 |
| 8 | BS_C05FKR8X | Supratentorial Ependymoma | — | 0.798 |
| 9 | TCGA-OR-A5KY-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.797 |
| 10 | MDT-AP-0513 | Med | Medulloblastoma | 0.797 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.550 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.520 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.430 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.420 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.410 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.310 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.300 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.270 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.240 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.230 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.180 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.170 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.160 | Inavolisib | — uncovered |
| HYPOXIA | 0.130 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.120 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.120 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.120 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.110 | Idelalisib | — uncovered |